Clinical Trials
CALM Therapy Suitability in Malignant Glioma Caregivers: Phase 1a Stakeholder Trial
Willis et alPalliative & Supportive Care

Managing Cancer and Living Meaningfully (CALM) therapy is an established psychotherapeutic framework for addressing end-of-life distress, but its feasibility and acceptability have not been formally established among caregivers facing the unique neurocognitive and functional trajectories of malignant glioma. In this Phase 1a Define trial, investigators evaluated the suitability of CALM therapy using stakeholder feedback to inform protocol adaptations prior to pilot testing.
The study included 22 bereaved caregivers of patients diagnosed with malignant glioma who participated in focus groups and completed caregiver-reported outcome measures. Focus group discussions evaluated the relevance of CALM, identified barriers to engagement, and gathered recommendations to tailor its content and delivery structure. Qualitative data were evaluated using thematic, deductive, latent analysis, achieving high inter-rater reliability among coders (kappa = 0.86).
Qualitative analysis revealed that caregivers found CALM highly applicable to the malignant glioma caregiving trajectory. Perceived benefits included emotional support, enhanced role preparedness, improved self-efficacy, better communication with patients, and access to specialized care. However, several critical implementation challenges were identified, most notably caregiver exhaustion and time restrictions, hesitation to burden patients with emotional vulnerability, and uncertainty regarding whether patients possessed sufficient cognitive or emotional reserve to engage. Stakeholders recommended expanding the intervention to explicitly address caregiver burden and bereavement, as well as refining operational logistics including timing, presentation format, and session scheduling. These findings validate the acceptability of the intervention framework and justify advancing an optimized, neuro-oncology-tailored CALM protocol into pilot efficacy testing.
Key Takeaways
- Qualitative evaluation confirmed the high relevance of CALM therapy for malignant glioma caregivers, showing potential to enhance emotional well-being, caregiving self-efficacy, preparedness, and dyadic communication (inter-coder agreement kappa = 0.86).
- Primary barriers to caregiver participation included limited time and energy, reluctance to burden patients with emotional disclosures, and concerns regarding patient cognitive or emotional capacity to engage.
- Caregiver feedback supports tailoring the CALM intervention by incorporating dedicated modules on burden and bereavement and modifying delivery logistics prior to pilot clinical trials.
Read the original sourcePalliative & Supportive Care
